Topic · Cancer Mechanisms and Therapy
Most cited papers in Cancer Mechanisms and Therapy
What are the most cited papers in Cancer Mechanisms and Therapy?
The most cited paper in Cancer Mechanisms and Therapy is "The 2007 WHO Classification of Tumours of the Central Nervous System" (Hiroko Ohgaki, Otmar Dieter Wiestler, Webster K. Cavenee et al., 2007), with 14,012 citations. Next come "Mutations of the BRAF gene in human cancer" (10,791) and "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma" (7,547).
Showing 50 of 100 papers. Every paper with more than 1,030 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | The 2007 WHO Classification of Tumours of the Central Nervous System Hiroko Ohgaki, Otmar Dieter Wiestler, Webster K. Cavenee et al. · Digital Access to Scholarship at Harvard (DASH) (Harvard University) | 2007 | 14,012 |
| 2 | Mutations of the BRAF gene in human cancer Helen Ruth Davies et al. · Nature | Jun 2002 | 10,791 |
| 3 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn et al. · New England Journal of Medicine | 13 May 2020 | 7,547 |
| 4 | Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis Vincenzo Mazzaferro, Enrico Regalia, Roberto Doci et al. · New England Journal of Medicine | 14 Mar 1996 | 7,221 |
| 5 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science | 26 Apr 2007 | 4,504 |
| 6 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix et al. · The Lancet | 5 Dec 2016 | 3,732 |
| 7 | MAP kinase signalling pathways in cancer Amardeep S. Dhillon, Suzanne Hagan, Oliver Rath et al. · Oncogene | 14 May 2007 | 3,062 |
| 8 | Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival Josep Maria Llovet, Jordi Bruix · Hepatology | Feb 2003 | 3,039 |
| 9 | Stat3 as an Oncogene Jacqueline Bromberg, Melissa H Wrzeszczynska, Geeta Devgan et al. · Cell | Aug 1999 | 2,805 |
| 10 | Oncogenes and signal transduction Lewis C. Cantley, Kurt R. Auger, Christopher F Carpenter et al. · Cell | 1991 | 2,762 |
| 11 | Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation L. A. Liotta, Patricia Schriver Steeg, William George Stetler‐Stevenson · Cell | 1991 | 2,761 |
| 12 | Signal integration by JNK and p38 MAPK pathways in cancer development Erwin Friedrich Wagner, Ángel R. Nebreda · Nature reviews. Cancer | 24 Jul 2009 | 2,672 |
| 13 | Targeting apoptosis in cancer therapy Benedito A. Carneiro, Wafik S. El‐Deiry · Nature Reviews Clinical Oncology | 23 Mar 2020 | 2,659 |
| 14 | Met, metastasis, motility and more Carmen Birchmeier, Walter Birchmeier, Ermanno Gherardi et al. · Nature Reviews Molecular Cell Biology | Dec 2003 | 2,620 |
| 15 | Targeting cancer with small molecule kinase inhibitors Jianming Zhang, Priscilla Li-ning Yang, Nathanael S. Gray · Nature reviews. Cancer | 19 Dec 2008 | 2,601 |
| 16 | Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN Vuk Stambolic, Akira Suzuki, José Luís de la Pompa et al. · Cell | Oct 1998 | 2,587 |
| 17 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management Jesús M. Bañales et al. · Nature Reviews Gastroenterology & Hepatology | 30 Jun 2020 | 2,543 |
| 18 | ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions Philippe P. Roux, John Blenis · Microbiology and Molecular Biology Reviews | Jun 2004 | 2,528 |
| 19 | Targeting PI3K signalling in cancer: opportunities, challenges and limitations Jeffrey A. Engelman · Nature reviews. Cancer | 24 Jul 2009 | 2,481 |
| 20 | Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer Klarisa Rikova et al. · Cell | Dec 2007 | 2,334 |
| 21 | The STATs of cancer — new molecular targets come of age Hua Yu, Richard Jove · Nature reviews. Cancer | Feb 2004 | 2,294 |
| 22 | Revisiting STAT3 signalling in cancer: new and unexpected biological functions Hua Yu, Heehyoung Lee, Andreas Peter Herrmann et al. · Nature reviews. Cancer | 24 Oct 2014 | 2,184 |
| 23 | Tumor metastasis: mechanistic insights and clinical challenges Patricia Schriver Steeg · Nature Medicine | Aug 2006 | 2,152 |
| 24 | PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Antonino Glaviano et al. · Molecular Cancer | 18 Aug 2023 | 2,108 |
| 25 | Molecular therapies and precision medicine for hepatocellular carcinoma Josep Maria Llovet, Robert Montal, Daniela Sia et al. · Nature Reviews Clinical Oncology | 30 Jul 2018 | 2,055 |
| 26 | Tumor angiogenesis: causes, consequences, challenges and opportunities Roberta Lugano, Mohanraj Ramachandran, Anna Dimberg · Cellular and Molecular Life Sciences | 6 Nov 2019 | 2,006 |
| 27 | Neurotrophin signal transduction in the nervous system David R. Kaplan, Freda D. Miller · Current Opinion in Neurobiology | Jun 2000 | 1,959 |
| 28 | Targeting PI3K/Akt signal transduction for cancer therapy Yan He, Miao Sun, Guo Geng Zhang et al. · Signal Transduction and Targeted Therapy | 16 Dec 2021 | 1,927 |
| 29 | The Different Mechanisms of Cancer Drug Resistance: A Brief Review Behzad Mansoori, Ali Mohammadi, Sadaf Davudian et al. · Advanced Pharmaceutical Bulletin | 25 Sep 2017 | 1,924 |
| 30 | Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis Yu Sun, Wenzhou Liu, Tao Liu et al. · Journal of Receptors and Signal Transduction | 22 Jun 2015 | 1,922 |
| 31 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Gideon E. Bollag et al. · Nature | Sep 2010 | 1,850 |
| 32 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Scott M. Wilhelm, Christopher J. Carter, Mark John Lynch et al. · Nature Reviews Drug Discovery | Oct 2006 | 1,843 |
| 33 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology | 11 Dec 2021 | 1,749 |
| 34 | Tumor angiogenesis: molecular pathways and therapeutic targets Sara M. Weis, David A. Cheresh · Nature Medicine | Nov 2011 | 1,748 |
| 35 | STATs in oncogenesis Tammy L. Bowman, Roy Garcia, James Turkson et al. · Oncogene | 25 May 2000 | 1,741 |
| 36 | How MAP Kinases Are Regulated Melanie H. Cobb, Elizabeth J. Goldsmith · Journal of Biological Chemistry | Jun 1995 | 1,736 |
| 37 | Small molecules in targeted cancer therapy: advances, challenges, and future perspectives Lei Zhong, Yueshan Li, Liang Xiong et al. · Signal Transduction and Targeted Therapy | 30 May 2021 | 1,707 |
| 38 | Delineation of prognostic biomarkers in prostate cancer Saravana Mohan Dhanasekaran, Terrence R. Barrette, Debashis Ghosh et al. · Nature | Aug 2001 | 1,691 |
| 39 | Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies Giuseppa Pistritto, Daniela Trisciuoglio, Claudia Ceci et al. · Aging | 27 Mar 2016 | 1,690 |
| 40 | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Georgia Hatzivassiliou et al. · Nature | 3 Feb 2010 | 1,653 |
| 41 | PD-1/PD-L1 pathway: current researches in cancer. Yanyan Han, Dandan Liu, Lianhong Li · PubMed | 2020 | 1,641 |
| 42 | Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Raffaella Sordella, Daphne W. Bell, Daniel A. Haber et al. · Science | 29 Jul 2004 | 1,620 |
| 43 | Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies Julita Machlowska, Jacek Baj, Monika Sitarz et al. · International Journal of Molecular Sciences | 4 Jun 2020 | 1,601 |
| 44 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib James M. Bean et al. · Proceedings of the National Academy of Sciences | 18 Dec 2007 | 1,598 |
| 45 | Targeting PI3K in cancer: mechanisms and advances in clinical trials Jing Yang, Ji Nie, Xuelei Ma et al. · Molecular Cancer | 19 Feb 2019 | 1,580 |
| 46 | Independent Human MAP-Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms Benoît Dérijard, Joël Raingeaud, Tamera Barrett et al. · Science | 3 Feb 1995 | 1,572 |
| 47 | Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5 Li Liu, Yichen Cao, Charles Chen et al. · Cancer Research | 15 Dec 2006 | 1,555 |
| 48 | JNK signaling in apoptosis Danny N. Dhanasekaran, E. Premkumar Reddy · Oncogene | 20 Oct 2008 | 1,546 |
| 49 | The JNK signal transduction pathway Chris J. Weston · Current Opinion in Genetics & Development | Feb 2002 | 1,539 |
| 50 | Challenges in liver cancer and possible treatment approaches David Anwanwan, Santosh Kumar Singh, Shriti Singh et al. · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2 Nov 2019 | 1,536 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.